In October 1998, as a result of the efforts of Claude Schulman from Erasmus University and Gary Kelloff from the National Cancer Institute, a group of urologists and interested scientists met in Brussels to discuss strategies for the chemoprevention of prostate cancer. There was unanimity that this exciting new approach carried considerable potential, since the disease is highly prevalent, and there is good evidence for progression from pre-cancer to actual prostate cancer. Current strategies for reducing prostate cancer deaths such as early detection as well as therapy of clinically apparent disease, are imperfect since they are not always effective, and moreover they carry with them a signi®cant downside in terms of a negative impact on the individual patient's quality of life.
As with other cancers, development of a rational chemopreventative strategy requires an understanding of the major mechanisms of carcinogenesis involved in tumour development. Many of the genetic aberrations in what has been aptly described`this multistep process of progressive disorganisation' have recently been elucidated. Many of them seem potentially amenable to modi®cation by a number of putative chemopreventative agents. As we move into an era of potential gene therapy many more opportunities may present themselves.
Chemoprevention may be de®ned as the administration of agents to prevent induction of cancer, or to inhibit or delay its progression. The group discussed in detail the A,B,C of strategies for chemoprevention of prostate cancer. Well characterised Agents need to be identi®ed, reliable intermediate Biomarkers must be available, and ®nally suitable Cohorts of patients must be recruited to participate in the studies.
Preliminary experimental or epidemiological data suggesting both chemopreventative ef®cacy and, most importantly, safety on chronic administration are also necessary. Ideally, a mechanistic rationale for the putative chemopreventative activity observed should be to hand.
Currently, the most promising chemopreventative agents include retinoids, antiandrogens, 5 a-reductase inhibitors, antioestrogens, steroid aromatase inhibitors, vitamins D and E, selenium, lycopene and 2-di¯uoro-methylornithine. Phase II trials will be of critical importance in evaluating some or all of them for genuine chemopreventative safety and ef®cacy.
The criteria for clinically valuable biomarkers are that they ®t expected biological mechanisms, can be assayed reliably and quantitatively, and correlate with observed cancer incidence. Prostatic intraepithelial neoplasia (PIN) was argued by David Bostwick from the Mayo Clinic to match these criteria. He reported that changes in PIN correlates signi®cantly with the incidence of prostate cancer and can be relatively easily quanti®ed histologically and from a number of other measures including nuclear polymorphism, nucleolar size, and DNA ploidy. He outlined other potentially useful biomarkers, such as those associated with cellular proliferation kinetics (such as proliferating cell nuclear antigen and apoptosis), differentiation, genetic damage (such as loss of heterozygosity on chromosome 8), signal transduction, angiogenesis and secretion of prostate speci®c antigen (PSA).
Several cohorts of patients were proposed as candidates for phase II studies. These included men without actual prostate cancer but those who are at increased risk of the disease because of increased PSA levels at baseline and/or those with pre-existing PIN. It was emphasised that these studies must attempt to quantify the effectiveness of an agent to modify the risk of developing the disease and will inevitably require large numbers of subjects.
Richard Sylvester described the currently ongoing evaluation of the 5 a-reductase inhibitor ®nasteride as a possible chemopreventative agent. This seven-year study, which is now fully recruited, involves the randomisation of 18 000 men, who consented to initial prostate biopsy at the outset of the trial, to either daily ®nasteride 5 mg or inactive placebo, and then careful follow-up with sequential PSA measurements. Patients are scheduled to undergo repeat prostatic biopsy at the end of the study so that the tissue effects of the agent can be de®ned.
The conclusion at the end of the meeting was that this new approach carried considerable potential. The old adage that`prevention is better than cure' seems particularly appropriate in the case of prostate cancer, a disease that is destined to affect one man in ten during their lifetime, often with devastating consequences.
